Scholars Central

Conference abstractPublished 29 Oct 2012

Validating MDM2 oncogene as a cancer target

Authors: Ruiwen Zhang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Oncogene addition is one of the major characteristics of human malignancies. Targeting oncogene can be one of the most effective approaches to cancer therapy. We have been interested in developing oncogene inhibitors as novel cancer drug. We and others have suggested that the mdm2 oncogene be a valuable target for cancer therapy and prevention. Overexpression of mdm2 is often seen in various human cancers and correlates with high-grade, late-stage, and more treatment-resistant tumors. MDM2 is a major negative regulator of p53, the most studied tumor suppressor thus far. The MDM2-p53 auto-regulatory loop has been extensively investigated and is an attractive cancer target, which indeed has been the main focus of anti-MDM2 drug discovery. Much effort has been expended in the development of small molecule MDM2 antagonists targeting the MDM2-p53 interaction, and a few of these have advanced into clinical trials. However, MDM2 exerts its oncogenic activity through both p53- dependent and -independent mechanisms. Recently, there is an increasing interest in identifying natural MDM2 inhibitors; some of them have been shown to decrease MDM2 expression and activity in vitro and in vivo. These identified synthetic and natural MDM2 inhibitors include a plethora of diverse chemical frameworks, this presentation will focus on their biological activities in vitro and in vivo and the underlying molecular mechanisms of action, targeting MDM2 itself, regulators of MDM2, and/or the MDM2-p53 interaction. These MDM2 inhibitors can be used alone or in combination with conventional treatments, improving the prospects for cancer therapy and prevention. Their complex and unique molecular architectures may provide a stimulus for developing synthetic analogs in the future. (Supported by NIH grants R01 CA112029 and R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731.)

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ruiwen Zhang”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels